These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 21058409)

  • 1. Pegylated liposomal doxorubicin and gemcitabine in patients with advanced hepatocellular carcinoma: results of a phase 2 study.
    Lombardi G; Zustovich F; Farinati F; Cillo U; Vitale A; Zanus G; Donach M; Farina M; Zovato S; Pastorelli D
    Cancer; 2011 Jan; 117(1):125-33. PubMed ID: 21058409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pegylated liposomal doxorubicin-based combination chemotherapy as salvage treatment in patients with advanced hepatocellular carcinoma.
    Poh SB; Bai LY; Chen PM
    Am J Clin Oncol; 2005 Dec; 28(6):540-6. PubMed ID: 16317261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gemcitabine and doxorubicin for the treatment of patients with advanced hepatocellular carcinoma: a phase I-II trial.
    Yang TS; Wang CH; Hsieh RK; Chen JS; Fung MC
    Ann Oncol; 2002 Nov; 13(11):1771-8. PubMed ID: 12419750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II randomized controlled study of pegylated liposomal doxorubicin and carboplatin vs. gemcitabine and carboplatin for platinum-sensitive recurrent ovarian cancer (GOTIC003/intergroup study).
    Fujiwara H; Ushijima K; Nagao S; Takei Y; Shimada M; Takano M; Yoshino K; Kawano Y; Hirashima Y; Nagase S; Nishio S; Nishikawa T; Ito K; Shoji T; Kimura E; Takano T; Sugiyama T; Kigawa J; Fujiwara K; Suzuki M
    Int J Clin Oncol; 2019 Oct; 24(10):1284-1291. PubMed ID: 31127479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of combination chemotherapy in early relapsed epithelial ovarian cancer using gemcitabine and pegylated liposomal doxorubicin.
    Mirza MR; Lund B; Lindegaard JC; Keldsen N; Mellemgaard A; Christensen RD; Bertelsen K
    Gynecol Oncol; 2010 Oct; 119(1):26-31. PubMed ID: 20638711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pegylated liposomal doxorubicin and gemcitabine in a fixed dose rate infusion for the treatment of patients with poor prognosis of recurrent ovarian cancer: a phase Ib study.
    Crespo G; Sierra M; Losa R; Berros JP; Villanueva N; Fra J; Fonseca PJ; Luque M; Fernández Y; Blay P; Sanmamed M; Muriel C; Esteban E; Lacave AJ
    Int J Gynecol Cancer; 2011 Apr; 21(3):478-85. PubMed ID: 21436695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of pegylated liposomal doxorubicin (Caelyx) plus Gemcitabine in chemotherapeutically pretreated patients with advanced breast cancer.
    Ulrich-Pur H; Kornek GV; Haider K; Kwasny W; Payrits T; Dworan N; Vormittag L; Depisch D; Lang F; Scheithauer W
    Acta Oncol; 2007; 46(2):208-13. PubMed ID: 17453371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of pegylated liposomal doxorubicin plus gemcitabine in heavily pretreated metastatic breast cancer patients: Long-term results from a single institution experience.
    Martin-Romano P; Baraibar I; Espinós J; Legaspi J; López-Picazo JM; Aramendía JM; Fernández OA; Santisteban M
    Breast J; 2018 Jul; 24(4):473-479. PubMed ID: 29286192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pilot study evaluating the efficacy and toxicity of biweekly gemcitabine and pegylated liposomal doxorubicin in recurrent platinum-resistant epithelial ovarian cancer.
    Tas F; Guney N; Derin D; Aydiner A; Topuz E
    Int J Clin Oncol; 2008 Apr; 13(2):156-60. PubMed ID: 18463961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pegylated liposomal doxorubicin and gemcitabine in the front-line treatment of recurrent/metastatic breast cancer: a multicentre phase II study.
    Adamo V; Lorusso V; Rossello R; Adamo B; Ferraro G; Lorusso D; Condemi G; Priolo D; Di Lullo L; Paglia A; Pisconti S; Scambia G; Ferrandina G
    Br J Cancer; 2008 Jun; 98(12):1916-21. PubMed ID: 18493232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gemcitabine and liposomal doxorubicin in biliary and hepatic carcinoma (HCC) chemotherapy: preliminary results and review of the literature.
    Pastorelli D; Cartei G; Zustovich F; Marchese F; Artioli G; Zovato S; Binato S; Ceravolo R; Cingarlini S; Salmaso F; Mattiazzi M; Sanavio C; Farinati F; Zanus G; Cillo U
    Ann Oncol; 2006 May; 17 Suppl 5():v153-7. PubMed ID: 16807446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and toxicity of gemcitabine and pegylated liposomal Doxorubicin in recurrent platinum-resistant/refractory epithelial ovarian cancer.
    Karaoglu A; Arslan UY; Ozkan M; Kalender ME; Alici S; Coskun U; Gumus M; Celenkoglu G; Er O; Sevinc A; Buyukberber S; Alkis N; Benekli M;
    Asian Pac J Cancer Prev; 2009; 10(1):63-6. PubMed ID: 19469626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of pegylated liposomal doxorubicin in combination with gemcitabine in metastatic breast cancer patients.
    Jacquin JP; Chargari C; Thorin J; Mille D; Mélis A; Orfeuvre H; Clavreul G; Chaigneau L; Nourissat A; Dumanoir C; Savary J; Merrouche Y; Magné N
    Am J Clin Oncol; 2012 Feb; 35(1):18-21. PubMed ID: 21278560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carboplatin/gemcitabine alternating with carboplatin/pegylated liposomal doxorubicin and carboplatin/cyclophosphamide in platinum-refractory/resistant paclitaxel - pretreated ovarian carcinoma.
    Pectasides D; Pectasides E; Papaxoinis G; Psyrri A; Pliarchopoulou K; Koumarianou A; Macheras A; Athanasas G; Xiros N; Economopoulos T
    Gynecol Oncol; 2010 Jul; 118(1):52-7. PubMed ID: 20406710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine and pegylated liposomal doxorubicin alternating with cisplatin plus cyclophosphamide in platinum refractory/resistant, paclitaxel-pretreated, ovarian carcinoma.
    Pectasides D; Xiros N; Papaxoinis G; Aravantinos G; Sykiotis C; Pectasides E; Psyrri A; Koumarianou A; Gaglia A; Gouveris P; Economopoulos T
    Gynecol Oncol; 2008 Jan; 108(1):47-52. PubMed ID: 17915300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR).
    Sehouli J; Chekerov R; Reinthaller A; Richter R; Gonzalez-Martin A; Harter P; Woopen H; Petru E; Hanker LC; Keil E; Wimberger P; Klare P; Kurzeder C; Hilpert F; Belau AK; Zeimet A; Bover-Barcelo I; Canzler U; Mahner S; Meier W
    Ann Oncol; 2016 Dec; 27(12):2236-2241. PubMed ID: 27789470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paclitaxel and gemcitabine vs. paclitaxel and pegylated liposomal doxorubicin in advanced non-nasopharyngeal head and neck cancer. An efficacy and cost analysis randomized study conducted by the Hellenic Cooperative Oncology Group.
    Fountzilas G; Papakostas P; Dafni U; Makatsoris T; Karina M; Kalogera-Fountzila A; Maniadakis N; Aravantinos G; Syrigos K; Bamias A; Christodoulou C; Economopoulos T; Kalofonos H; Nikolaou A; Angouridakis N; Stathopoulos G; Bafaloukos D; Pavlidis N; Daniilidis J
    Ann Oncol; 2006 Oct; 17(10):1560-7. PubMed ID: 16790517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer.
    Rivera E; Valero V; Arun B; Royce M; Adinin R; Hoelzer K; Walters R; Wade JL; Pusztai L; Hortobagyi GN
    J Clin Oncol; 2003 Sep; 21(17):3249-54. PubMed ID: 12947059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pegylated liposomal doxorubicin in combination with gemcitabine: a phase II study in anthracycline-naïve and anthracycline pretreated metastatic breast cancer patients.
    Fabi A; Ferretti G; Papaldo P; Salesi N; Ciccarese M; Lorusso V; Carlini P; Carpino A; Mottolese M; Cianciulli AM; Giannarelli D; Sperduti I; Felici A; Cognetti F
    Cancer Chemother Pharmacol; 2006 May; 57(5):615-23. PubMed ID: 16163541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules.
    Taïeb J; Bonyhay L; Golli L; Ducreux M; Boleslawski E; Tigaud JM; de Baere T; Mansourbakht T; Delgado MA; Hannoun L; Poynard T; Boige V
    Cancer; 2003 Dec; 98(12):2664-70. PubMed ID: 14669287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.